p53 gene determines radiation efficacy:
This article was originally published in Clinica
Executive Summary
The status of an individual's p53 gene product may have a bearing on how effective radiation is for treating some prostate cancer patients, say US researchers. Under normal conditions, the natural tumour-killing effects of the p53 gene product can be activated or enhanced by radiation therapy. An abnormal or mutated gene, however, renders it unable to suppress tumours or facilitate the killing of tumour cells by radiation, researchers from the University of Winconsin Comprehensive Cancer Center, report in the International Journal of Radiation Oncology, Biology and Physics (July).
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.